<DOC>
	<DOCNO>NCT00467259</DOCNO>
	<brief_summary>This study design evaluate endometrial safety testosterone patch treatment low libido naturally postmenopausal woman .</brief_summary>
	<brief_title>Endometrial Safety Study Transdermal Testosterone ( 300 Mcg/Day ) Naturally Postmenopausal Women</brief_title>
	<detailed_description>Naturally postmenopausal woman hypoactive sexual desire disorder ( HSDD ) randomize 52-week , multicenter , double-blind ( DB ) , parallel-group , placebo-controlled study . Patients stratify base whether use concomitant estrogen/progestin therapy randomize 4:1 ration receive either testosterone transdermal system ( 300 mcg/day ) placebo . Patients use estrogen/progestin start study maintain therapy throughout study ; patient use estrogen/progestin start study initiate estrogen/progestin therapy throughout study . Endometrial biopsy transvaginal ultrasound collected/performed screen study exit patient . Safety assess adverse event , report vaginal bleeding , lipid , serum chemistry , hematology . Physical exam , pap smear , mammogram monitor .</detailed_description>
	<mesh_term>Hypokinesia</mesh_term>
	<mesh_term>Sexual Dysfunctions , Psychological</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Women screen study participation must least one year post menopausal , 4570 year old , general good health , may may hormone therapy , must low sexual desire cause distress . Women screen study participation must use androgen therapy medical , physical , psychological , pharmacological condition could make participation unsafe confound safety evaluation .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Natural Menopause</keyword>
</DOC>